Patient-centric care in primary immune thrombocytopenia (ITP): shared decision-making and assessment of health-related quality of life

References

• Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386–2393. doi:10.1182/blood-2008-07-162503
   PubMed Web of Science ®Google Scholar
• Zufferey A, Kapur R, Semple JW. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J Clin Med. 2017;6(2):16.
   PubMed Web of Science ®Google Scholar
• Hato T, Shimada N, Kurata Y, et al. Risk factors for skin, mucosal, and organ bleeding in adults with primary ITP: a nationwide study in Japan. Blood Adv. 2020;4(8):1648–1655. doi:10.1182/bloodadvances.2020001446
   PubMed Web of Science ®Google Scholar
• Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–3866. doi:10.1182/bloodadvances.2019000966
   PubMed Web of Science ®Google Scholar
• Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780–3817. doi:10.1182/bloodadvances.2019000812
   PubMed Web of Science ®Google Scholar
• Khellaf M, Charles-Nelson A, Fain O, et al. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 2014;124(22):3228–3236.
   PubMed Web of Science ®Google Scholar
• Trotter P, Hill QA. Immune thrombocytopenia: improving quality of life and patient outcomes. Patient Relat Outcome Meas. 2018;Volume 9:369–384. doi:10.2147/PROM.S140932
   Google Scholar
• Cooper N, Cuker A, Bonner N, et al. Qualitative study to support the content validity of the immune thrombocytopenia (ITP) Life Quality Index (ILQI). Br J Haematol. 2021;194(4):759–766. doi:10.1111/bjh.17694
   PubMed Web of Science ®Google Scholar
• Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) World Impact Survey (iWISh): patient and physician perceptions of diagnosis, signs and symptoms, and treatment. Am J Hematol. 2021;96(2):188–198. doi:10.1002/ajh.26045
   PubMed Web of Science ®Google Scholar
• Cooper N, Kruse A, Kruse C, et al. Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): impact of ITP on health-related quality of life. Am J Hematol. 2021;96(2):199–207. doi:10.1002/ajh.26036
   PubMed Web of Science ®Google Scholar
• Hill QA, Newland AC. Fatigue in immune thrombocytopenia. Br J Haematol. 2015;170(2):141–149. doi:10.1111/bjh.13385
   PubMed Web of Science ®Google Scholar
• Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377(9763):393–402. doi:10.1016/S0140-6736(10)60959-2
   PubMed Web of Science ®Google Scholar
• Meyer O, Schlag R, Stauch T, et al. Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag – results of the 5th Interim Analysis of the Study RISA, with Special Consideration of Treatment Discontinuations. American Society of Hematology. New Orleans, Louisiana, 2022.
   Google Scholar
• Khelif A, Saleh MN, Salama A, et al. Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: findings from the EXTEND study. Am J Hematol. 2019;94(2):200–208. doi:10.1002/ajh.25348
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Cronin A, Arnold DM, et al. Extensive variability in platelet, bleeding, and QOL outcome measures in adult and pediatric ITP: communication from the ISTH SSC subcommittee on platelet immunology. J Thromb Haemost. 2021;19(9):2348–2354. doi:10.1111/jth.15366
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl Med J. 2010;363(20):1889–1899. doi:10.1056/NEJMoa1002625
   PubMed Web of Science ®Google Scholar
• George JN, Mathias SD, Go RS, et al. Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol. 2009;144(3):409–415. doi:10.1111/j.1365-2141.2008.07464.x
   PubMed Web of Science ®Google Scholar
• Brown TM, Horblyuk RV, Grotzinger KM, et al. Patient-reported treatment burden of chronic immune thrombocytopenia therapies. BMC Blood Disord. 2012;12(2):1471.
   Google Scholar
• Matzdorff A, Meyer O, Ostermann H, et al. Immune thrombocytopenia– current diagnostics and therapy: recommendations of a joint working group of DGHO, OGHO, SGH, GPOH, and DGTI. Oncol Res Treat. 2018;41:1–30. doi:10.1159/000492187
   PubMed Web of Science ®Google Scholar
• Terrell DR, Neunert CE, Cooper N, et al. Immune Thrombocytopenia (ITP): current limitations in patient management. Medicina (Kaunas). 2020;56(12):667.
   PubMed Web of Science ®Google Scholar
• Guidry JA, George JN, Vesely SK, et al. Corticosteroid side-effects and risk for bleeding in immune thrombocytopenic purpura: patient and hematologist perspectives. Eur J Haematol. 2009;83(3):175–182. doi:10.1111/j.1600-0609.2009.01265.x
   PubMed Web of Science ®Google Scholar
• Matzdorff AC, Arnold G, Salama A, et al. Advances in ITP—therapy and quality of life—a patient survey. PLoS One. 2011;6(11):e27350. doi:10.1371/journal.pone.0027350
   PubMed Web of Science ®Google Scholar
• Cuker A, Liebman HA. Corticosteroid overuse in adults with immune thrombocytopenia: cause for concern. Res Pract Thromb Haemost. 2021;5(6):e12592. doi:10.1002/rth2.12592
   PubMed Web of Science ®Google Scholar
• Kruse C, Kruse A, DiRaimo J. Immune thrombocytopenia: the patient’s perspective. Annals of Blood. 2020;6:9.
   Google Scholar
• Cooper N, Kruse C, Kruse A, et al. Patient perceptions on splenectomy outcomes: results from the ITP World Impact Survey (I-WISH). HemaSphere. 2019;3.S1(312); abstract PF714.
   Google Scholar
• Sanz MA, Aledort L, Mathias SD, et al. Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP). Value Health. 2011;14(1):90–96. doi:10.1016/j.jval.2010.10.017
   PubMed Web of Science ®Google Scholar
• Kuter DJ, Mathias SD, Rummel M, et al. Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care. Am J Hematol. 2012;87(5):558–561. doi:10.1002/ajh.23163
   PubMed Web of Science ®Google Scholar
• Rovó A, Cantoni N, Samii K, et al. Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: results from a questionnaire conducted in Switzerland, Austria, and Belgium. PLoS One. 2022;17(4):e0267342. doi:10.1371/journal.pone.0267342
   PubMed Web of Science ®Google Scholar
• McDonald V, Newland A, Morgan M, et al. Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in the United Kingdom and Ireland (TRAPeze UK & IE study). Hematology. 2021;26(1):799–808. doi:10.1080/16078454.2021.1978689
   PubMed Web of Science ®Google Scholar
• Jansen AG, McDonald V, Newland A, et al. P1636: patient preferences and experiences regarding Thrombopoietin-Receptor Agonists For Immune Thrombocytopenia In The Netherlands (TRAPEZE NL STUDY). HemaSphere. 2022;6(Suppl):1517–1518.
   Google Scholar
• Lucchesi A, Lovrencic B, McDonald V, et al. PCR246 patient preferences regarding Thrombopoietin-Receptor Agonists for Immune Thrombocytopenia in Italy (TRAPeze Italy Study). Value Health. 2022;25(12):S437–S438. doi:10.1016/j.jval.2022.09.2179
   Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Shared decision making. Available from: www.nice.org.uk/guidance/ng197 (accessed 2023 Mar 28).
   Google Scholar
• U.S. Food and Drug Administration. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. Available from: https://www.fda.gov/media/77832/download (accessed 2023 Apr 13).
   Google Scholar
• Hjollund IN, Larsen PL, Biering K, et al. Use of patient-reported outcome (PRO) measures at group and patient levels: experiences from the generic integrated PRO system, WestChronic. Interact J Med Res. 2014;3(1):e5.
   PubMedGoogle Scholar
• Kirsch M, Klaassen RJ, Geest Sd, et al. Understanding the importance of using patient-reported outcome measures in patients with immune thrombocytopenia. Semin Hematol. 2013;50(Suppl 1):S39–S42. doi:10.1053/j.seminhematol.2013.03.007
   PubMedGoogle Scholar
• Snyder CF, Mathias SD, Cella D, et al. Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey. Curr Med Res Opin. 2008;24(10):2767–2776. doi:10.1185/03007990802377461
   PubMed Web of Science ®Google Scholar
• Viana R, D'Alessio D, Grant L, et al. Psychometric evaluation of ITP Life Quality Index (ILQI) in a global survey of patients with immune thrombocytopenia. Adv Ther. 2021;38(12):5791–5808. doi:10.1007/s12325-021-01934-0
   PubMed Web of Science ®Google Scholar
• Mathias SD, Bussel JB, George JN, et al. A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes. 2007;5:11. doi:10.1186/1477-7525-5-11
   PubMed Web of Science ®Google Scholar
• Mathias SD, Gao SK, Rutstein M, et al. Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences. Curr Med Res Opin. 2009;25(2):375–383. doi:10.1185/03007990802634119
   PubMed Web of Science ®Google Scholar
• Klaassen RJ, Blanchette VS, Barnard D, et al. Validity, reliability, and responsiveness of a new measure of health-related quality of life in children with immune thrombocytopenic purpura: the Kids’ ITP Tools. J Pediatr. 2007;150(5):510-5. 515.e1. doi:10.1016/j.jpeds.2007.01.037
   PubMed Web of Science ®Google Scholar
• Klaassen RJ, Blanchette V, Burke TA, et al. Quality of life in childhood immune thrombocytopenia: international validation of the kids’ ITP tools. Pediatr Blood Cancer. 2013;60(1):95–100. doi:10.1002/pbc.24257
   PubMed Web of Science ®Google Scholar
• Webster K, Cella D, Yost K. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes. 2003;1:79. doi:10.1186/1477-7525-1-79
   PubMedGoogle Scholar
• Jensen RE, Rothrock NE, DeWitt EM, et al. The role of technical advances in the adoption and integration of patient-reported outcomes in clinical care. Med Care. 2015;53(2):153–159. doi:10.1097/MLR.0000000000000289
   PubMed Web of Science ®Google Scholar
• Coulter A, Collins A. Making shared decision-making a reality. The King's Fund. 2011. https://assets.kingsfund.org.uk/f/256914/x/73b4098901/making_shared_decisions_making_reality_july_2011.pdf
   Google Scholar
• General Medical Council. Decision making and consent. 2020.
   Google Scholar
• NHS England and NHS Improvement. Shared Decision Making Summary guide 2019.
   Google Scholar
• Newland A, Hill Q, Morgan M, et al. Making the right choices in ITP management and care: a shared decision making toolkit for patients.
   Google Scholar
• Popoola VO, Lau BD, Shihab HM, et al. Patient preferences for receiving education on venous thromboembolism prevention - a survey of stakeholder organizations. PLoS One. 2016;11(3):e0152084. doi:10.1371/journal.pone.0152084
   PubMed Web of Science ®Google Scholar
• Chakrabarti P, George B, Shanmukhaiah C, et al. How do patients and physicians perceive immune thrombocytopenia (ITP) as a disease? Results from Indian analysis of ITP World Impact Survey (I-WISh). J Patient Rep Outcomes. 2022;6(1):24. doi:10.1186/s41687-022-00429-y
   PubMedGoogle Scholar
• The ITP Support Association. Understanding the challenges faced by patients by patients with ITP (Immune Thrombocytopenia) HROMBOCYTOPENIA). Available from: https://www.itpsupport.org.uk/images/downloads/ITP_Understanding%20the%20challenges_Report%202020.6.pdf (accessed 2023 Apr 27).
   Google Scholar
• ChipApk. Trombocytopenia Disease apk. Available from: https://chipapk.com/app/3196009/ (accessed 2023 Mar 24).
   Google Scholar
• Florio. Who we are. Available from: https://florio.com/ (accessed 2023 Mar 24).
   Google Scholar
• Novartis. Introducing the Immune Thrombocytopenia (ITP) Pocket Log. Available from: https://www.novartis.com/ie-en/stories/introducing-immune-thrombocytopenia-itp-pocket-log (accessed 2023 Mar 24).
   Google Scholar
• RK Unit. How to increase a low platelet. Available from: https://play.google.com/store/apps/details?id = com.mami.HoIncreaLlaCou&hl = en&gl = US (accessed 2023 Mar 24).
   Google Scholar
• International ITP Alliance. International ITP alliance. Available from: https://www.globalitp.org/ (accessed 2023 Jul 19).
   Google Scholar
• Mead N, Bower P. Patient-centredness: a conceptual framework and review of the empirical literature. Soc Sci Med. (1982) 2000;51(7):1087–1110. doi:10.1016/S0277-9536(00)00098-8
   Google Scholar
• Britt E, Hudson SM, Blampied NM. Motivational interviewing in health settings: a review. Patient Educ Couns. 2004;53(2):147–155. doi:10.1016/S0738-3991(03)00141-1
   PubMed Web of Science ®Google Scholar
• Hirsch JK, Sirois FM. Hope and fatigue in chronic illness: the role of perceived stress. J Health Psychol. 2016;21(4):451–456. doi:10.1177/1359105314527142
   PubMed Web of Science ®Google Scholar
• White MH, Bennett CM. Fatigue is common in paediatric immune thrombocytopenia and improves with second-line treatments. Br J Haematol. 2020;191(1):15–16. doi:10.1111/bjh.16855
   PubMed Web of Science ®Google Scholar
• Grace RF, Klaassen RJ, Shimano K. Fatigue in children and adolescents with immune thrombocytopenia. Br J Haematol. 2020;191(1):98–106. doi:10.1111/bjh.16751
   PubMed Web of Science ®Google Scholar
• Bower JE, Lamkin DM. Inflammation and cancer-related fatigue: mechanisms, contributing factors, and treatment implications. Brain Behav Immun. 2013;30(Suppl):S48–S57. doi:10.1016/j.bbi.2012.06.011
   PubMedGoogle Scholar
• van Dijk WE, Nap-van der Vlist MM, Knoop H, et al. Possible targets to reduce fatigue in chronic immune thrombocytopenia patients – an explorative stud. Th Open. 2022;6(4):e387–e395. doi:10.1055/s-0042-1758546
   PubMedGoogle Scholar
• Lins L, Carvalho F. SF-36 total score as a single measure of health-related quality of life: scoping review. SAGE Open Med. 2016;4:2050312116671725.
   Web of Science ®Google Scholar
• EuroQol Research Foundation. EQ-5D. Available from: https://euroqol.org/ (accessed 2023 Mar 29).
   Google Scholar
• Thompson E. Hamilton Rating Scale for Anxiety (HAM-A). Occup Med (Chic Ill). 2015;65(7):601.
   Web of Science ®Google Scholar
• FACIT.org. FACIT-Fatigue. Available from: https://www.facit.org/measures/FACIT-Fatigue (accessed 2023 Apr 13).
   Google Scholar
• FACIT.org. FACT-Th6 Functional Assessment of Cancer Therapy - Thrombocytopenia 6 Item Version. Available from: https://www.facit.org/measures/FACT-Th6 (accessed 2023 Mar 29).
   Google Scholar
• Cella D, Beaumont JL, Webster KA, et al. Measuring the concerns of cancer patients with low platelet counts: the Functional Assessment of Cancer Therapy–Thrombocytopenia (FACT-Th) questionnaire. Support Care Cancer. 2006;14(12):1220–1231. doi:10.1007/s00520-006-0102-1
   PubMed Web of Science ®Google Scholar
• Larson R. Psychometric properties of the modified fatigue impact scale. Int J MS Care. 2013;15(1):15–20. doi:10.7224/1537-2073.2012-019
   PubMedGoogle Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–365. doi:10.1007/BF03260126
   PubMed Web of Science ®Google Scholar
• Smets EM, Garssen B, Bonke B, et al. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39(3):315–325. doi:10.1016/0022-3999(94)00125-O
   PubMed Web of Science ®Google Scholar
• Dencker A, Sunnerhagen KS, Taft C, et al. Multidimensional fatigue inventory and post-polio syndrome - a Rasch analysis. Health Qual Life Outcomes. 2015;13:20. doi:10.1186/s12955-015-0213-9
   PubMed Web of Science ®Google Scholar
• Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121–1123. doi:10.1001/archneur.1989.00520460115022
   PubMed Web of Science ®Google Scholar
• Valko PO, Bassetti CL, Bloch KE, et al. Validation of the fatigue severity scale in a Swiss cohort. Sleep. 2008;31(11):1601–1607. doi:10.1093/sleep/31.11.1601
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang L, Quan M, et al. Health-related quality of life in children with chronic immune thrombocytopenia in China. Health Qual Life Outcomes. 2016;14:45.
   PubMedGoogle Scholar